Immuno-hormonal regulation of tumor metastasis in breast cancer patients

Aim. To determine the participation of estradiol and progesterone (E2 and Pg), hormone-specific idiotypic and antiidiotypic antibodies and antibodies against benzo[a]pyrene (Bp) in the regulation of tumor metastasis in breast cancer patients (BCP). Materials and Methods. There were studied 475 BCP II stage (254 – without metastases and 221 – with metastases). Test-systems “ImmunoEA-Estradiol” and “ImmunoEA-Pg” (Immunotech, Moscow) were performed for blood serum E2 and Pg concentration analysis before antitumor treatment. Enzyme-linked immunosorbent assay was used for study of IgA1 and IgG1 antibodies against E2, Pg and Bp and antiidiotypic antibodies (IgG2). Associations of these serum factors with tumor metastasis were studies by CART-analysis. Results. There were revealed the correlation of IgA1-Bp with IgA1-E2 and IgA1-Pg (rs = 0.71 and rs = 0.60; p < 0.01), IgG1-Bp with IgG1-E2 and IgG1-Pg (rs = 0.75 and r s = 0.69; p < 0.01). Concentration of E2 and Pg were no correlated with studied idiotypic and antiidiotypic antibodies levels. There was revealed 5 groups of BCP with definite personal IgG2-Pg + IgA1-Bp combinations associated with metastases significantly. Metastatic tumors were revealed in 51 BCP (group 1.1) with low levels of IgG2-Pg ≤ 2.19 cu + IgA1-Bp ≤ 2.21 cu rarely than in 137 BCP (group 2) with IgG2-Pg ≤ 2.19 cu + IgA1-Bp>2.21 cu (21.6% vs 46.0 %; p = 0,004). Metastasis were detected in 15 BCP (group 2.1) with IgG2-Pg 2.19–3.6 cu + IgA1-Bp levels ≤ 1.41cu frequently than in 199 (group 2.2) with IgG2-Pg 2.19– 3.6 cu + IgA1-Bp>1.41cu (86.7 vs 53.3; p = 0,026). Metastases were found in 73 BCP (group 3) with high IgG2-Pg>3.6 cu rarely (38.4%), vs groups 2.1 (p = 0.002) and group 2.2 (p = 0.04). Conclusion. IgG2-Pg may inhibit whereas IgA1-Bp may stimulate the tumor metastasis in BCP II stage with definite personal combinations.